Oncology Clinical Trials in Oklahoma City, OK
As of July 2026, 147 paid clinical trials are recruiting for Oncology in Oklahoma City, Oklahoma. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Oklahoma City
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
148 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
A Phase 1/1b Study of IAM1363 in HER2 Cancers
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Prospective Study to Assess a Diagnostic Aid for Cancer
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
GEMINI-NSCLC: NSCLC Biomarker Study
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
QTX3034 in Patients With KRAS G12D Mutation
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
A Study of NX-1607 in Adults With Advanced Malignancies
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Study of AVZO-021 in Patients With Advanced Solid Tumors
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
About research studies in Oklahoma City
Oklahoma City has approximately 595 recruiting research studies across a wide range of therapeutic areas. Oklahoma hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Top Research Study Locations in Oklahoma City
Researchers run research studies in Oklahoma City, OK at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| University of Oklahoma Health Sciences Center | Acute Myeloid Leukemia, Stage IV Lung Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8 | 183 |
| Mercy Hospital Oklahoma City | Malignant Solid Neoplasm, Anatomic Stage II Breast Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8 | 50 |
| University of Oklahoma | Endometrial Cancer, Colorectal Cancer, Ovarian Cancer | 26 |
| OU Health Stephenson Cancer Center | Ovarian Cancer, AML With Mutated NPM1, Acute Myeloid Leukemia | 19 |
| Stephenson Cancer Center | Cervical Cancer, Endometrial Cancer, Ovarian Cancer | 14 |
| Oklahoma Medical Research Foundation | Systemic Lupus Erythematosus, Aging, Multiple Sclerosis | 11 |
| The University of Oklahoma Health Sciences Center | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 11 |
| Hightower Clinical | Acute Migraine, Antineutrophil Cytoplasmic Antibody-associated Vasculitis, Cancer | 10 |
| Oklahoma Heart Hospital | Acute Decompensated Heart Failure, Aortic Stenosis, CHF | 8 |
| TSET Health Promotion Research Center | CRC (Colorectal Cancer), CRC Screening, Smoking Cessation | 8 |
| Integris Southwest Medical Center | Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Advanced Esophageal Adenocarcinoma | 6 |
| Lynn Health Science Institute | Obesity or Overweight, Hypercholesterolemia, Rheumatoid Arthritis | 5 |
| Sooner Clinical Research | Major Depressive Disorder, Autism Spectrum Disorder, Bipolar Depression | 5 |
| University of Oklahoma Health Campus | Amyloid Pathology, Brain Activity, Brain Aging | 5 |
| University of Oklahoma Health Science Center | Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML or ANLL), Autoimmune Diseases | 5 |
| University of Oklahoma Health Sciences | Acute Respiratory Distress Syndrome, Breast Cancer Survivor, Cancer Survivorship | 5 |
| Integris Baptist Medical Center | Cardiovascular Diseases, Pulmonary Hypertension, Connective Tissue Diseases | 5 |
| Integris Cancer Institute of Oklahoma | Stage IIIB Lung Cancer AJCC v8, Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | 4 |
| Oklahoma Children's Hospital | Anesthesia, Asthma Attack, Asthma in Children | 4 |
| Oklahoma Proton Center | Breast Cancer, Breast Neoplasm, Breast Tumor | 4 |
| South Oklahoma Heart Research | Acute Coronary Syndrome, Heart Failure, Heart Failure With Mildly Reduced Ejection Fraction | 4 |
| Unity Clinical Research | Atopic Dermatitis, Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa | 4 |
| Dean McGee Eye Institute | Choroidal Melanoma, Indeterminate Lesions, Ocular Melanoma | 3 |
| GSK Investigational Site | Asthma, Alzheimer's Disease | 3 |
| OU Health University of Oklahoma Medical Center | Acquired Antithrombin Deficiency, Carcinoma, Non-Small Cell Lung, Cutaneous Squamous Cell Cancer | 3 |
Active & Upcoming Studies in Oklahoma City (2026)
Recruiting trials in Oklahoma City grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (258 active studies)
- Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · Phase 1, Phase 2 · National Cancer Institute (NCI)
- INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study · University of Alabama at Birmingham
Cardiovascular (39 active studies)
- A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) · Phase 1 · Vasa Therapeutics
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease · Phase 3 · Alnylam Pharmaceuticals
Diabetes & metabolic (24 active studies)
- Impact of Chia Seeds on Human Breast Milk Composition · University of Oklahoma
- Disulfiram in Rheumatoid Arthritis · Phase 2 · University of Oklahoma
Neurology & pain (24 active studies)
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine · Phase 3 · Kallyope Inc.
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine · Phase 3 · Kallyope Inc.
Mental health & behavior (23 active studies)
- Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia · Phase 3 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation · Phase 2 · University of Oklahoma
Pediatric (7 active studies)
- Supraglottic Airway for Resuscitation Trial · Children's Hospital of Philadelphia
- iAmHealthy Clinical Practice Guideline (CPG) · University of Kansas Medical Center
Vaccines (3 active studies)
- Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children · Phase 3 · University of Alabama at Birmingham
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) · Duke University
Eye & vision (3 active studies)
- Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant · Phase 2, Phase 3 · Glaukos Corporation
- A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma · Phase 3 · AbbVie
Common conditions studied in Oklahoma City
- Endometrial Cancer (15 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Myeloid Leukemia (13 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Ovarian Cancer (13 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Malignant Solid Neoplasm (10 active studies). Recruiting Malignant Solid Neoplasm studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Breast Cancer (9 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Major Depressive Disorder (9 active studies). Major depressive disorder research examines rapid-acting agents, augmentation strategies, and digital therapeutics for treatment-resistant cases.
Leading research sponsors in Oklahoma City
- University of Oklahoma
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- NRG Oncology
- SWOG Cancer Research Network
Local regulations and guidelines
Clinical trials in Oklahoma are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Oklahoma research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Oklahoma City. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Oklahoma City
Hipa.ai aggregates every recruiting study in Oklahoma City from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Oklahoma City?
There are approximately 595 recruiting clinical trials in Oklahoma City, Oklahoma listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Oklahoma City pay participants?
Most recruiting trials in Oklahoma City compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Oklahoma City?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Oklahoma City?
The most common conditions under active study in Oklahoma City include Endometrial Cancer (15), Acute Myeloid Leukemia (13), Ovarian Cancer (13), Malignant Solid Neoplasm (10), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Oklahoma City?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Oklahoma City on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Oklahoma City?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Oklahoma City?
Recruiting research sites in Oklahoma City include University of Oklahoma Health Sciences Center, Mercy Hospital Oklahoma City, University of Oklahoma, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Oklahoma City right now?
The largest active categories in Oklahoma City are Cancer & tumors (258), Cardiovascular (39), Diabetes & metabolic (24). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.